Study of a drug for breast cancer that has spread to a few spots
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HER2-positive (a specific protein on the cancer cells).
- The cancer must have spread to no more than 5 separate spots, and not in a spread-out way.
- You must not have had any treatment for the spread (metastatic) cancer yet, except hormone therapy or radiation for cure.
- You must be able to do your daily activities without much help (WHO performance status 0 or 1).
- You must have a clear scan showing the cancer can be measured.
- If the cancer came back after treatment, there must be at least 24 months since you were cancer-free.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
This study looks at how well the drug trastuzumab deruxtecan works in women with breast cancer that has spread. It is for patients who have already taken this drug.
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests two targeted drugs, trastuzumab rezetecan and trastuzumab deruxtecan, to see which works better for HER2-positive breast cancer that has spread or cannot be removed by surgery. These drugs target the HER2 protein on cancer cells to slow or stop their growth.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.